

## AMENDMENT TO THE CLAIMS

1. (Currently Amended) A method of determining whether a human test subject has, is at risk of developing, or has an increased likelihood ~~may have or be at risk~~ of developing a titin-related disease or condition of the heart, said method comprising obtaining a sample from said test subject and analyzing a nucleic acid molecule of said sample to determine whether the test subject has a mutation in a naturally occurring human *titin* gene, wherein the presence of said mutation is an indication that said test subject has, is at risk of developing, or has an increased likelihood ~~may have or be at risk~~ of developing a titin-related disease or condition of the heart.

2. (Previously Presented) The method of claim 1, wherein said analyzing of said nucleic acid molecule comprises using nucleic acid molecule primers specific for the *titin* gene for nucleic acid molecule amplification of the *titin* gene by the polymerase chain reaction.

3. (Previously Presented) The method of claim 1, wherein said analyzing of said nucleic acid molecule comprises sequencing *titin* nucleic acid molecules from said test subject.

4-5. (Canceled).

6. (Original) The method of claim 1, wherein said disease or condition is heart failure.

7. (Canceled).

8. (Withdrawn) A method for identifying a compound that can be used to treat or to prevent heart failure, said method comprising contacting an organism comprising a *titin* mutation and having a phenotype characteristic of heart failure with said compound, and determining the effect of said compound on said phenotype, wherein detection of an improvement in said phenotype indicates the identification of a compound that can be used to treat or to prevent heart failure.

9. (Withdrawn) The method of claim 8, wherein said organism is a zebrafish.

10. (Withdrawn) The method of claim 8, wherein said *titin* mutation is the *pickwick* mutation.

11. (Withdrawn) A method of treating or preventing heart failure in a patient, said method comprising administering to said patient a compound identified using the method of claim 8.

12. (Withdrawn) The method of claim 11, wherein said patient has a mutation in the *titin* gene.

13. (Withdrawn) The method of claim 12, wherein said mutation is the *pickwick* mutation.

14. (Withdrawn) A non-human animal comprising a mutation in a *titin* gene.
15. (Withdrawn) The non-human animal of claim 14, wherein the non-human animal is a zebrafish.
16. (Withdrawn) The non-human animal of claim 14, wherein the mutation is in a cardiac-specific exon of said *titin* gene.
17. (Withdrawn) The non-human animal of claim 16, wherein the mutation is in the N2B exon of said *titin* gene.
18. (Withdrawn) The non-human animal of claim 14, wherein the mutation results in the presence of a stop codon in said *titin* gene.
19. (Withdrawn) The non-human animal of claim 14, wherein the mutation is the *pickwick* mutation.
20. (Currently Amended) The method of claim 1, wherein the test subject has an increased likelihood ~~may have or be at risk~~ of developing a titin-related disease or condition.
21. (Previously Presented) The method of claim 1, wherein the mutation is in a cardiac-specific exon of said *titin* gene.

22. (Previously Presented) The method of claim 1, wherein the mutation is in the N2B exon of said *titin* gene.

23. (Previously Presented) A method of determining whether a test subject has an increased likelihood of a titin-related disease or condition of the heart, or facilitating determination of the etiology of an existing heart condition, the method comprising obtaining a sample from the test subject and analyzing a nucleic acid molecule of the sample to determine whether the test subject has a mutation in a *titin* gene, wherein the presence of a mutation in a *titin* gene is an indication that the test subject has an increased likelihood of a titin-related disease or condition of the heart, or provides information as to the etiology of an existing heart disease or condition.

24. (Previously Presented) The method of claim 23, wherein the method is carried out to determine whether the test subject has an increased likelihood of a titin-related disease or condition of the heart.

25. (Previously Presented) The method of claim 23, wherein the method is carried out to facilitate determination of the etiology of an existing heart disease or condition in the test subject.

26. (Previously Presented) The method of claim 23, wherein said analyzing of said nucleic acid molecule comprises using nucleic acid molecule primers specific for the *titin* gene

for nucleic acid molecule amplification of the *titin* gene by the polymerase chain reaction.

27. (Previously Presented) The method of claim 23, wherein said analyzing of said nucleic acid molecule comprises sequencing *titin* nucleic acid molecules from said test subject.

28. (Previously Presented) The method of claim 23, wherein said test subject is a mammal.

29. (Previously Presented) The method of claim 23, wherein said test subject is human.

30. (Previously Presented) The method of claim 23, wherein said disease or condition is heart failure.

31. (Previously Presented) The method of claim 23, wherein the mutation is in a cardiac-specific exon of said *titin* gene.

32. (Previously Presented) The method of claim 23, wherein the mutation is in the N2B exon of said *titin* gene.